

SS 3?  
fpat fr2346017

-1- (WPAT)

AN - 78-06805A/04 (06805A)

TI - Compsns. contg. a beidellitic intergrade smectite - for treatment  
of gastrointestinal disorders

DC - B06

PA - (SOCI ) SOC CIV RECH SCIENT

NP - 1

PN - FR2346017-A 77.12.02 (7804)

PR - 75.10.23 75FR-032400

IC - A61K-033/00 C01B-033/20

AB - Therapeutic compsns. for disorders of the gastro-intestinal tract  
contain an beidellitic intergrade smectite (1.4 nm. phyllite) (I)  
together with suitable excipients. Used for treatment of  
oesophagitis, gastritis, gastro-duodenitis hiatal hernias,  
gastro-duodenal ulcers, colitis, etc.

A typical compsn. contains 3 g (I), 0.125 g co-dried  
aluminium hydroxide-magnesium carbonate gel, about 0.040 g  
liquorice extract, about 0.004 g vanillin, about 0.007 g sodium  
saccharin, about 0.2 g pectin and about 0.749 g hydrated glucose.

BEST AVAILABLE COPY

# DERWENT PUBLICATIONS LTD.

06805

06805A/04 SOCI CIV RECH SCIENT 23.10.75-FR-032400 (02.12.77) A61k-33 C01b 33 20 Compsns. contg. a beidellitic intergrade smectite - for treatment of gastrointestinal disorders	B06 SOCI 23.10.75 FR 2346 017	B(5-A1B, 5-B2C, 12-E8, 12-G2, 12-H1). 5	50
<p>Therapeutic compsns. for disorders of the gastro-intestinal tract contain a beidellitic intergrade smectite (14 mm phyllite) together with suitable excipients.</p> <p><u>USE</u></p> <p>Treatment of oesophagitis, gastritis, gastro-duodenitis, hiatal hernias, gastro-duodenal ulcers, colitis, etc. (I) absorbs toxins (esp. bacterial toxins), swells to cover and protect gastrointestinal mucous membranes, promotes the cicatrization of lesions and neutralises excess gastric acidity.</p> <p><u>DETAILS</u></p> <p>(I) is found in certain deposits in the Vaucluse district of France. It is an aluminium magnesium double silicate in which some of the aluminium in its octahedral layer has been replaced by iron, magnesium or calcium. It has a good swelling and adsorbing power (e.g. it absorbs <math>\geq 300</math> mg. of strychnine sulphate per g.).</p> <p>It is prepared as follows: the mineral is crushed, separated from gravel and the like, and suspended in water. The suspension is treated with a strong mineral acid at ambient temp. and pH 2-3. After 1 hour the dispersion is diluted and separated granulometrically in a series of hydrocyclones. The fraction retained on a 0.100 mm mesh sieve is thickened and dried below 200 °C.</p> <p><u>TOXICITY</u></p> <p>Rats given 200 mg/kg/day or 2 g/kg/day of (I) orally for 6 months showed no toxic symptoms.</p> <p><u>EXAMPLE</u></p> <p>Sachets for oral administration contained the following: (I) (3 g.), aluminium hydroxide-magnesium carbonate gel (0.125 g.), licorice extract (0.040 g.), vanillin (0.004 g.), sodium saccharin (0.007 g.), pectin (0.200 g.) and hydrated glucose (0.740 g.). (10pp520).</p>		06805A	
06806A/04		FR2346017	

06806

06806A/04 RICLA RADIOTECHNIQ 30.03.76 FR-009145 (02.12.77) B01b 17 06	L03 PHIG 30.03.76 FR 2346-045	L(3-D2A).	50
pregnated with C on one of its faces when it is desirable to avoid the concn. of impurities due to adsorption by the gra-			